Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

E2F1 and KIAA0191 expression predicts breast cancer patient survival.

Authors: Hallett, RM  Hassell, JA 
Citation: Hallett RM and Hassell JA, BMC Res Notes. 2011 Mar 31;4:95. doi: 10.1186/1756-0500-4-95.
Pubmed: (View Article at PubMed) PMID:21453498
DOI: Full-text: DOI:10.1186/1756-0500-4-95

BACKGROUND: Gene expression profiling of human breast tumors has uncovered several molecular signatures that can divide breast cancer patients into good and poor outcome groups. However, these signatures typically comprise many genes (~50-100), and the prognostic tests associated with identifying these signatures in patient tumor specimens require complicated methods, which are not routinely available in most hospital pathology laboratories, thus limiting their use. Hence, there is a need for more practical methods to predict patient survival. METHODS: We modified a feature selection algorithm and used survival analysis to derive a 2-gene signature that accurately predicts breast cancer patient survival. RESULTS: We developed a tree based decision method that segregated patients into various risk groups using KIAA0191 expression in the context of E2F1 expression levels. This approach led to highly accurate survival predictions in a large cohort of breast cancer patients using only a 2-gene signature. CONCLUSIONS: Our observations suggest a possible relationship between E2F1 and KIAA0191 expression that is relevant to the pathogenesis of breast cancer. Furthermore, our findings raise the prospect that the practicality of patient prognosis methods may be improved by reducing the number of genes required for analysis. Indeed, our E2F1/KIAA0191 2-gene signature would be highly amenable for an immunohistochemistry based test, which is commonly used in hospital laboratories.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 11530014
Created: 2016-08-18
Species: All species
Last Modified: 2016-08-18
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.